Navigation Links
Innophos Holdings, Inc. Reports Fourth Quarter And Full Year 2012 Results
Date:2/14/2013

012, level with 2011.

For the fourth quarter 2012, operating income of $5 million was down $5 million from fourth quarter 2011 levels, but up $2 million sequentially.  The variance against prior year is primarily due to lower sales, along with $2 million of planned maintenance outage expenses in the current quarter.
Operating income margin was 10% for the 2012 fourth quarter, below the full year average, as a result of the higher maintenance expense. 

GTSP & OtherGTSP & Other sales (primarily fertilizer co-product) increased 6% for 2012 compared to 2011, with volumes up 19% but prices down 13% on average.  Market prices increased during the first half of 2012, but fell throughout the second half, returning back to the seasonal lows seen at the beginning of the year.For the fourth quarter, sales increased 2% compared to fourth quarter 2011, with volumes up 14%, but prices down 12%.GTSP & Other recorded $2 million of operating income in 2012 compared to $21 million for 2011.  Included in the 2012 results is $7 million of income related to the settlement with Rhodia over Mexican water duties charges and $2 million of adjustments related to prior periods.  2011 included $3 million of income resulting from a reduction in the provision for excess Mexican water duties charges.  Excluding these adjustments, 2012 had an operating loss of $3 million compared to an operating income of $18 million for 2011.  Operating income margins were -3% for 2012 compared to 18% for 2011, excluding the noted adjustments.

For the fourth quarter 2012, GTSP & Other was just above break-even at $0.5 million, down $4 million from the year ago period on a combination of lower phosphate fertilizer market prices and relatively high market raw material costs.  Operating income margins were 2% for the fourth quarter 2012 compared to 20% for the fourth quarter 2011.

Recent Trends and OutlookMarket demand was flat t
'/>"/>

SOURCE Innophos Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Innophos Holdings, Inc. Schedules Call to Discuss Fourth Quarter And Full Year 2012 Results
2. Innophos To Present At 2012 KeyBanc Capital Markets Basic Materials & Packaging Conference
3. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
4. Free Research Report on Laboratory Corp. of America Holdings, Sony Corp., Cyberonics, Inc., Olin Corp. and Deluxe Corp.
5. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
6. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
7. China Pharma Holdings, Inc. Reports Third Quarter 2012 Financial Results
8. Zimmer Holdings, Inc. Reports Third Quarter 2012 Financial Results
9. China Pharma Holdings, Inc. Reports Second Quarter 2012 Financial Results
10. RxAlly Member Pharmacies Invited To Become The Preferred Network For Smart Insurance Company Holdings, Inc.
11. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... focused on the development and commercialization of novel bile ... the pricing of an underwritten public offering of 1,730,000 ... price of $33.01 per share.  In addition, Intercept has ... to an additional 259,500 shares of common stock. ...
(Date:6/18/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: ... announced public offering of common shares (the "Offering"). Pursuant ... shares at a price of $85.00 per share, for ... will file a final prospectus supplement to its effective ... a similar filing with the securities regulatory authorities in ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... Sept. 16 Boston Scientific Corporation (NYSE: ... Drug Administration (FDA) has approved an expanded indication for ... CRT-D.  The exclusive expanded indication is effective immediately and ... the FDA for patients in all New York Heart ...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory ... do not adequately demonstrate that the potential benefits of ... a population of overweight and obese individuals to allow ...
Cached Medicine Technology:Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 2Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 3Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds 4Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 2Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 3Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 4
(Date:6/18/2013)... New York (PRWEB) June 18, 2013 ... dedicated to protecting the rights of victims injured by ... University’s independent review of Medtronic’s Infuse bone graft products ... Internal Medicine, a medical journal, the two studies serve ... difference in effectiveness” when comparing Infuse and the traditional ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
(Date:6/18/2013)... shown that cancer cells have a much different ... scientists at The University of Texas at Dallas have ... strategy to combat lung cancer. , In an article ... ONE , UT Dallas researchers compared the metabolic characteristics ... taken from the same patient. , They found ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ages 13 ... for Disease Control and Prevention (CDC). Of those, nearly 20 ... HIV Testing Day on June 27, Allsup, a nationwide provider ... CDC and other organizations are raising awareness of the importance ... new HIV infections each year. Along with developing AIDS, those ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from respiratory ... of a silicone treatment for gluteus augmentation at Cuerpos Health ... by a mystery Venezuelan doctor in a center that was ... Vazquez of Bayshore Cosmetic Surgery , women suffering from ... not board certified is more common than people think. ...
Breaking Medicine News(10 mins):Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... Defend Intellectual Property RightsINDIANAPOLIS, March 9 Eli Lilly ... the following statement after being granted a temporary restraining ... of Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals. Teva ... version prior to the resolution of outstanding patent litigation ...
... Neogen Corporation (Nasdaq: NEOG ) announced ... common stock repurchase program. In December, Neogen,s Board of ... have been, and additional shares are expected to be, ... depending on market conditions and other factors. Accordingly, there ...
... renders melanomas sensitive to retinoic acid and stops tumor ... cancer therapies such as radiotherapy, chemotherapy, and retinoic acid ... the prognosis for patients is often poor. However, Vincent ... the National Institutes of Health in Bethesda, Maryland, have ...
... Akerman Senterfitt today announced that Julie Gallagher has joined ... Healthcare Practice Group. Ms. Gallagher,s work focuses on ... companies, individual health care providers and health care facilities. ... she spent seven years as a shareholder."We are very ...
... to Announce Fiscal Third Quarter Results on ... Allscripts-Misys Healthcare Solutions, Inc. ("Allscripts") announced today ... to sell its Medication Services business to ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO )The transaction, which is anticipated ...
... Inc. (Nasdaq: KERX ) today announced that ... Listings Qualification Panel ("Panel") the determination of The Nasdaq ... The Nasdaq Capital Market due to noncompliance with Nasdaq ... a minimum of $2,500,000 in stockholders, equity, or $35,000,000 ...
Cached Medicine News:Health News:Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene 2Health News:Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene 3Health News:Neogen Reactivates Share Repurchase Program 2Health News:JCI online early table of contents: March 9, 2009 2Health News:JCI online early table of contents: March 9, 2009 3Health News:JCI online early table of contents: March 9, 2009 4Health News:JCI online early table of contents: March 9, 2009 5Health News:Julie Gallagher Joins Akerman Senterfitt's Healthcare Practice 2Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 2Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 3Health News:Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement 4Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 2Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: